advertisement
Abstract #109584 Published in IGR 24-1
Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety
Mathur MC; Ratnam PV; Saikumar SJ; John M; Ravishankar S; Dinesh MB; Chandil P; Pahuja K; Cherlikar V; Wadhwani S; Bendale P; Hazari A; Mishra R; Deshmukh S; Deshmukh S; Achlerkar RR; Shah DT; Hingorani C; Shah K; Topiwala P; Jani S; Rana VG; Majumdar NK; Chakrabarti D; Dey R; Halder D; Choudhury S; Kumar A; Das S; Nanda AK; Kumar VB; Dubey R; Kamdar GA; Pandey A; Kishanpuria S; Srivastava RM; Singh P; Verma SK; Sharma N; Gupta RIndian Journal of Ophthalmology 2023; 71: 2500-2503
PURPOSE: Glaucoma is the second leading cause of blindness worldwide, affecting more than 64 million people aged 40-80. The best way to manage primary open-angle glaucoma (POAG) is by lowering the intraocular pressure (IOP). Netarsudil is a Rho kinase inhibitor, the only class of antiglaucoma medications that reorganizes the extracellular matrix to improve the aqueous outflow through the trabecular pathway. METHODS: An open-label, real-world, multicentric, observation-based 3-month study was performed for assessing the safety and ocular hypotensive efficacy of netarsudil ophthalmic solution (0.02% w/v) in patients with elevated IOP. Patients were given netarsudil ophthalmic solution (0.02% w/v) as a first-line therapy. Diurnal IOP measurements, best-corrected visual acuity, and adverse event assessments were recorded at each of the five visits (Day-1: screening day and first dosing day; subsequent observations were taken at 2 weeks, 4 weeks, 6 weeks, and 3 months). RESULTS: Four hundred and sixty-nine patients from 39 centers throughout India completed the study. The mean IOP at baseline of the affected eyes was 24.84 ± 6.39 mmHg (mean ± standard deviation). After the first dose, the IOP was measured after 2, 4, and 6 weeks, with the final measurement taken at 3 months. The percentage reduction in IOP in glaucoma patients after 3 months of once-daily netarsudil 0.02% w/v solution use was 33.34%. The adverse effects experienced by patients were not severe in the majority of cases. Some adverse effects observed were redness, irritation, itching, and others, but only a small number of patients experienced severe reactions, as reported in a decreasing order: redness > irritation > watering > itching > stinging > blurring. CONCLUSION: We found that netarsudil 0.02% w/v solution monotherapy when used as the first-line treatment in primary open-angle glaucoma and ocular hypertension was both safe and effective.
Swarup Eye Centre, Swarup Eye Centre, Hyderabad, Telangana, India.
Full article